Home » Jiu’an Medical receives a regulatory letter from the 15 daily limit in 28 trading days | Jiu’an Medical | Regulatory Letter | Company Share Price_Sina Technology_Sina

Jiu’an Medical receives a regulatory letter from the 15 daily limit in 28 trading days | Jiu’an Medical | Regulatory Letter | Company Share Price_Sina Technology_Sina

by admin


Original Title: Jiu’an Medical Receives a Regulatory Letter, Going Out of 15 Daily Limits in 28 Trading Days

On December 15, Jiu’an Medical’s daily limit was closed at 25.14 yuan, which was the third consecutive trading day’s daily limit this week. Since November 8, the company’s stock price has risen by more than 300%, and the 15 daily limit has been exceeded in 28 trading days.

On the evening of the 14th, Jiu’an Medical announced that it had received a supervisory letter from the Shenzhen Stock Exchange. The regulatory letter shows that Jiu’an Medical’s response to the U.S. Food and Drug Administration’s emergency use authorization (EUA) on the kit’s progress on the interactive platform was earlier than the time disclosed in the designated media, which violated the “Stock Listing Rules (2020). Revision)” relevant regulations.

Jiu’an Medical disclosed on November 8, 2021, that the company’s US subsidiary iHealth Labs Inc.’s product new coronavirus antigen home self-test OTC kit has been authorized by the US Food and Drug Administration for emergency use, which can be used in the US public health emergency During the period, sales in the United States and countries or regions that recognize the U.S. EUA are expected to bring related sales revenue to the company in the future. The regulatory letter pointed out that starting from November 15, 2021, Jiu’an Medical has successively stated that “market demand is on an upward trend” when answering investor questions on the interactive e-commerce platform, and that “kits have been sold locally to the C-end and B-end” At the same time, “the official website of the kit sells at a price of US$6.99 (1 serving).” “The kit product belongs to the product category of the US federal government.” “The kit has begun mass production and is sold locally.” “The monthly production capacity of 100 million people is planned to be increased to 200 million people a month by the beginning of 2022.” “The US FDA’s review requirements are very strict. The application can be described as challenging. The information provided must be solid, rigorous, and strict. Implement in accordance with relevant requirements”, arousing greater concern in the market. Since November 15, 2021, the company’s stock price has risen by a daily limit for nine consecutive trading days, to a cumulative increase of 136.18% on November 25. During this period, the company disclosed three times in the “Announcement of Abnormal Stock Trading Fluctuations” that there is no information that should be disclosed without disclosure. It was not until November 26, 2021 that risk warnings were given in the “Stock Trading Risk Warning Announcement” regarding the aforementioned interactive response content, and the aforementioned interaction was not discussed in the “Announcement on the Reply to the Letter of Concern of the Shenzhen Stock Exchange” until November 30 Easy to answer the content to disclose and provide necessary explanations and risk warnings.

See also  Jiu'an Medical: American Subsidiary Signs Major Contracts for Daily Operation and Obtains Orders_Oriental Fortune Network

In the past month or so, the share price of Jiu’an Medical has risen rapidly. Flush data shows that from November 8th to December 15th, Jiu’an Medical’s stock price has risen by 319.00%, and the 15 daily limit has been exceeded in 28 trading days. Before this round of skyrocketing, the company’s stock price has shown a turbulent downward trend this year. From January 4 to November 12, it fell by 25.84%, and hit a new low of 5.80 yuan in intraday trading on October 28.

On the evening of November 23, Jiu’an Medical received a letter of concern from the Shenzhen Stock Exchange and was asked about the relevant situation of the kit product and whether there was any stock price that catered to the hot speculation. The company stated in a subsequent letter of concern that the company believes that there are no misleading statements or publicity, advertisements, or exaggerated statements in the response to the kit product on the Huiyiyi platform, and there is no use of the Huiyiyi platform to cater to market hotspots and hype. The situation of the company’s stock price.

The reporter noticed that Jiu’an Medical has frequent exchanges with investors on the investor interactive platform. This week, the company responded to about 30 questions on the Yihuiyi platform, many of which related to the production and sales of the kit. On December 14, the company said in response to investors’ questions that “the company has received orders from individual state governments (in the United States) and is vigorously supporting the epidemic prevention work of individual states.” “Just as investors have seen the news, Massachusetts , The New York State government has distributed iHealth’s new crown antigen kit products to the public to prepare for the prevention and control of the winter epidemic.” “Our company is constantly testing the evolution and activities of the epidemic new crown pneumonia strain variants, including Omicron mutations. Virus strains” and so on.

See also  Jiu'an Medical has fallen to the limit!Hot money institutions flee retail investors bravely to take over._Oriental Fortune Network


.

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy